Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease Yahoo Finance Nawigacja wpisu Short supply in children’s medicine leads locals to panic buy – News3LV Holy Grail Of Precision Medicine – Co-Development Of Therapeutics And Companion Diagnostics – Hasn’t Yet Achieved Its Potential – Forbes
